Menu
Explore Our Trials
Gateway for Cancer Research is one of the only nonprofits that exclusively funds innovative Phase I and Phase II cancer clinical trials for patients of all ages, regardless of cancer type. At the forefront of research and discovery, these early-phase trials are the first step in evaluating new cancer drugs, treatments, and therapies.
Results 41-50 of 59
Prostate Cancer
Impact of Cytoreductive Radical Prostatectomy on Oncologic and Quality of Life Outcome in Men with Newly Diagnosed Metastatic Prostate Cancer
Impact of Cytoreductive Radical Prostatectomy on Oncologic and Quality of Life Outcome in Men with Newly Diagnosed Metastatic Prostate Cancer Clinical Trial Summary: Prostate is the second most common non-skin cancer diagnosed and the second leading cause of cancer death in men. Furthermore, approximately 16% of prostate cancer patients present with late-stage disease. There is […]
Isaac Kim, MD, PhD, MBA
Yale University
Pediatric Blood Cancer
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial
LLS Pediatric Acute Leukemia (PedAL) Master Clinical Trial Summary: Therapeutic options for relapsed AML or some subsets of ALL remain limited. However, recent large-scale discovery efforts using next generation sequencing (NGS) methods have identified recurrent mutations, cellular signaling, and cell surface antigen targets for new therapies. This is a master trial that will screen each […]
Michele Redell, MD, PhD
Leukemia Lymphoma Society / Texas Children’s Cancer Center
Pediatric Blood Cancer
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies
A Phase I Study of Venetoclax in Combination with Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults with High-Risk Hematologic Malignancies Summary: Effective treatment for children and young adults with relapsed/refractory MDS, MDS-associated AML (MDS/AML), treatment related MDS/AML, and relapsed/refractory high-risk ALL/LBL continues to be a major clinical challenge with poor long-term […]
Andrew Place, MD, PhD
Dana-Farber Cancer Institute
Pediatric Blood Cancer
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy
PARPAML: A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination with Chemotherapy Summary: Currently, the survival of children diagnosed with AML sits at less than 70%. Despite 80 to 90% of patients achieving first complete remission, 30 to 40% will relapse and outcomes […]
Jennifer Kamens, MD
Stanford University
Pediatric Blood Cancer
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD
Serial Response and Biomarker-Guided Steroid Taper for Children with GVHD Summary: Allogeneic hematopoietic stem cell transplants (stem cell transplant from a donor) [HSCT] are an important treatment for high-risk hematologic (blood) malignancies. However, these transplants can result in graft versus host disease (GVHD) which targets the skin, liver, and GI tract. This occurs in about […]
John Levine, MD, MS
Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute
Pediatric Blood Cancer
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia
A Phase I and Expansion Cohort Study of Venetoclax and Selinexor in Combination with Chemotherapy in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia Summary: Survival rates for children with AML are greater than 60%; however, the outcome for patients with relapsed or refractory disease remains poor with less than 40% becoming long term […]
Jeffery Klco, MD, PhD
St. Jude Children's Research Hospital
Pediatric Brain Cancer
Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes
Exploiting Mutant IDH1/2-induced DNA Repair Defects in Pediatric Glioma to improve outcomes Summary: Pediatric gliomas are the most commonly encountered tumor types in children and also contribute to the most cancer related deaths in children. There is an urgent need for high-grade gliomas which lack any meaningful standard of care. IDH1/2 gene mutations are common […]
Sabine Mueller, MD, PhD
University of California, San Francisco
Pediatric Blood Cancer
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative Summary: Total body irradiation (TBI) in hematopoietic stem cell transplant (HSCT) has been a key element […]
Hisham Abdel-Azim, MD, MS
Children's Hospital Los Angeles
Solid Tumors
Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis
Fecal microbiota transplantation (FMT) treatment for immune checkpoint inhibitor–mediated colitis Summary: Immune checkpoint inhibitors (ICIs) have become paradigm-shifting therapies for a variety of cancers. However, these agents are associated with various toxicities that affect the skin, GI tract, liver, lungs, endocrine system, and nervous system. Immune-mediated colitis (IMC) is among the most encountered severe toxicities […]
Yinghong Wang, MD, PhD
MD Anderson Cancer Center
Breast Cancer
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL
Identification of Predictive Protein Pathway Activation Biomarkers for Neoadjuvant Breast Cancer Therapy Treatment from the ISPY2 TRIAL Summary: Over 200,000 women are diagnosed with breast cancer annually in the United States and breast cancer is responsible for approximately 45,000 deaths annually in the U.S. While those diagnosed with early-stage breast cancer have excellent outcomes, 10-20% […]
Emanuel Petricoin, PhD
George Mason University
